RNA-LNP Based, Non-Viral Delivery - RNA-LNP delivery avoids genome integration risks, leaving no genetic footprint. Optimized for PBMCs - The only non-viral kit proven effective for PBMC reprogramming ...

GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for ...

Personalized disease treatment, tailored to an individual’s genetic background, is the future of medicine. Stem cells hold the promise of that objective becoming a reality. A decade ago, the discovery ...

GERMANTOWN, MD / ACCESS Newswire / September 17, 2025 / uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, today announced the launch of its 2nd-Generation iPSC ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 / uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced ...

Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and ...

Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...